ArticleNature communications2024
Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
13.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 35 citations in OpenAlex.
- FDA-approved IMPDH inhibitors synergize with ribavirin to inhibit respiratory syncytial virus by interfering with purineEmerging microbes & infections · 2026Article
- Catching our breath: development of interventions and therapies for respiratory syncytial virus.Microbiology and molecular biology reviews : MMBR · 2026Review
- Advances in Detection Methods for Human Respiratory Syncytial Virus Neutralizing Antibodies.Vaccines · 2026Review
- Renaissance of farnesyltransferase inhibitors in cancer.Journal of translational medicine · 2026Review
- Structural Advances in Respiratory Syncytial Virus: Implications for Vaccine and Antiviral Development.Microorganisms · 2026Review
- Mucin-Inspired Filamentous Sulfated Copolymers Effectively Inhibit Human Respiratory Syncytial Virus (hRSV) Infectivity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Molecular mechanism of resistance to lonafarnib conferred by mutations in the cysteine-rich region of respiratory syncytial virus fusion glycoprotein and discovery of a lonafarnib-derived antiviral PROTAC.Journal of virology · 2026Article
- Molecular mechanism of ziresovir targeting the fusion glycoprotein of respiratory syncytial virus.PLoS pathogens · 2026Article
- βNature communications · 2025Article
- Article
- Status of advanced respiratory syncytial virus antiviral therapeutics 2025.Current opinion in virology · 2025Review
- High-throughput screens identify genotype-specific therapeutics for channelopathies.JCI insight · 2025Article
- Review
- Cangrelor and AVN-944 as repurposable candidate drugs for hMPV: analysis entailed by AI-driven in silico approach.Molecular diversity · 2025Article
- A pan-respiratory virus attachment inhibitor with high potency in human airway models and in vivo.Science advances · 2025Article
- Current antiviral therapies and promising drug candidates against respiratory syncytial virus infection.Virologica Sinica · 2025Review
- Advances in development of antiviral strategies against respiratory syncytial virus.Acta pharmaceutica Sinica. B · 2025Review
- Rational design of phytovirucide inhibiting nucleocapsid protein aggregation in tomato spotted wilt virus.Nature communications · 2025Article
- Repurposing of lonafarnib as a treatment for SARS-CoV-2 infection.JCI insight · 2025Article
- Both chebulagic acid and punicalagin inhibit respiratory syncytial virus entry via multi-targeting glycoprotein and fusion protein.Journal of virology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 9 institutions in 5 countries.
Svenja M SakeInstitute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, Hannover, Germany.
Xiaoyu ZhangInstitute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, Hannover, Germany.
Manoj Kumar RajakInstitute of Virology, Hannover Medical School, Hannover, Germany.
Melanie Urbanek-QuaingInstitute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, Hannover, Germany.ORCID 0000-0002-3629-9011
Arnaud CarpentierInstitute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, Hannover, Germany.ORCID 0000-0002-6994-4689
Antonia P GuneschInstitute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, Hannover, Germany.
Christina GretheInstitute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, Hannover, Germany.
Alina MatthaeiInstitute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, Hannover, Germany.
Jessica RückertInstitute of Virology, Hannover Medical School, Hannover, Germany.
Marie GallouxUniversité Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France.
Thibaut LarcherINRAE Oniris, PAnTher, APEX, Oniris, Nantes, France.ORCID 0000-0002-0396-3190
Ronan Le GofficUniversité Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France.ORCID 0000-0002-2012-0064
Fortune HontonnouUniversité Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France.
Arnab K ChatterjeeCalibr, Scripps Research, La Jolla, CA, USA.
Kristen JohnsonCalibr, Scripps Research, La Jolla, CA, USA.ORCID 0000-0003-0788-7217
Kaycie MorwoodCalibr, Scripps Research, La Jolla, CA, USA.
Katharina RoxDepartment of Chemical Biology, Helmholtz Center of Infection Research, Braunschweig, Germany.ORCID 0000-0002-8020-1384
Walid A M ElgaherHelmholtz Institute for Pharmaceutical Research Saarland (HIPS)-HZI, Saarbrücken, Germany.ORCID 0000-0002-8766-4568
Jiabin HuangInsitute for Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-3480-7115
Martin WetzkeDepartment for Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany.
Gesine HansenCluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany.
Nicole FischerInsitute for Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Jean-Francois EléouëtUniversité Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France.
Marie-Anne Rameix-WeltiUniversité Paris-Saclay, Université de Versailles St. Quentin; UMR 1173 (2I), INSERM; Assistance Publique des Hôpitaux de Paris, Hôpital Ambroise Paré, Laboratoire de Microbiologie, DMU15, Versailles, France.ORCID 0000-0002-5901-3856
Anna K H HirschHelmholtz Institute for Pharmaceutical Research Saarland (HIPS)-HZI, Saarbrücken, Germany.ORCID 0000-0001-8734-4663
Elisabeth HeroldCenter of Structural and Cell Biology in Medicine, Institute of Biochemistry, University of Luebeck, Luebeck, Germany.
Martin EmptingGerman Centre for Infection Research, Partner site Braunschweig-Hannover, Braunschweig, Germany.ORCID 0000-0002-0503-5830
Chris LauberInstitute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, Hannover, Germany.ORCID 0000-0002-2265-2953
Thomas F SchulzInstitute of Virology, Hannover Medical School, Hannover, Germany.ORCID 0000-0001-8792-5345
Thomas KreyInstitute of Virology, Hannover Medical School, Hannover, Germany.ORCID 0000-0002-4548-7241
Sibylle HaidInstitute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, Hannover, Germany. sibylle.haid@twincore.de.ORCID 0000-0001-5699-3097
Thomas PietschmannInstitute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, Hannover, Germany. thomas.pietschmann@twincore.de.ORCID 0000-0001-6789-4422
Medizinische Hochschule Hannover · DECenter for Experimental and Clinical Infection Research · DEUniversité de Versailles Saint-Quentin-en-Yvelines · FRScripps Research Institute · USUniversität Hamburg · DEGerman Center for Infection Research · DEInserm · FRInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement · FRUniversity of Lübeck · DE
Funding
Deutsche Forschungsgemeinschaft (German Research Foundation) EXC2155 RESIST_390874280Deutsche Forschungsgemeinschaft (German Research Foundation) EXC 2155 RESIST, Project 390874280Deutsche Forschungsgemeinschaft (German Research Foundation) EXC 2155 "RESIST" - Project ID 390874280Deutsches Zentrum für Infektionsforschung (German Center for Infection Research) DZIF, TTU 09.719Niedersächsische Ministerium für Wissenschaft und Kultur (Lower Saxony Ministry of Science and Culture) INDIRA 11-76251-99-6/19 (ZN3437)Niedersächsisches Ministerium für Wissenschaft und Kultur (Ministry for Science and Culture of Lower Saxony) INDIRA 11-76251-99-6/19 (ZN3437)Volkswagen Foundation (VolkswagenStiftung) OPTIS, ID9B811Volkswagen Foundation (VolkswagenStiftung) OPTIS, Project ID 9B811
Abstract
Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory tract infection in infants, older adults and the immunocompromised. Effective directly acting antivirals are not yet available for clinical use. To address this, we screen the ReFRAME drug-repurposing library consisting of 12,000 small molecules against RSV. We identify 21 primary candidates including RSV F and N protein inhibitors, five HSP90 and four IMPDH inhibitors. We select lonafarnib, a licensed farnesyltransferase inhibitor, and phase III candidate for hepatitis delta virus (HDV) therapy, for further follow-up. Dose-response analyses and plaque assays confirm the antiviral activity (IC
Indexed as
DibenzocycloheptenesPyridinesRespiratory Syncytial Virus InfectionsAnimalsDrug RepositioningFemaleMicePiperidinesViral Fusion ProteinsDibenzocyclohepteneslonafarnibPiperidinesPyridinesViral Fusion Proteins
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.